균상식육종 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global mycosis fungoides treatment market size is expected to reach USD 2.44 Billion in 2034 from USD 1.44 Billion in 2025, growing at a CAGR of 6.04 during 2026-2034.This market is growing steadily due to increasing awareness, diagnosis, and treatment of mycosis fungoides, a rare form of cutaneous T-cell lymphoma. Treatment options include topical therapies, phototherapy, radiation therapy, systemic medications, and targeted biologic treatments. Growing healthcare investments and advances in oncology research are contributing to market expansion. Improved diagnostic techniques are enabling earlier detection and more effective disease management.

The increasing focus on rare cancer treatment and personalized medicine is driving demand for innovative therapeutic approaches. Pharmaceutical companies are investing in research and development to improve treatment outcomes and expand available options. Rising adoption of targeted therapies and immunotherapy-based treatments is supporting market growth. Healthcare providers are also emphasizing multidisciplinary treatment strategies to improve patient quality of life and long-term outcomes.

Future prospects remain promising as ongoing clinical research continues to advance understanding of the disease. Development of novel therapies and precision medicine approaches is expected to enhance treatment effectiveness. Growing awareness among healthcare professionals and patients will support earlier diagnosis and intervention. As rare cancer research receives greater attention and funding, the mycosis fungoides treatment market is likely to experience sustained growth.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Drug Type

• Topical Steroids (Corticosteroid Creams or Ointments (Hydrocortisone, Clobetasol), Topical Steroid Lotions)
• Mechlorethamine (Topical Mechlorethamine (Nitrogen Mustard Cream), Injectable Mechlorethamine)

By Treatment Type

• Photodynamic Therapy
• Radiation Therapy
• Targeted Therapy
• Chemotherapy

By End User

• Hospitals
• Private Clinics
• Specialty Clinics

COMPANIES PROFILED

• Pfizer Inc., Merck & Co., Inc., Bristol Myers Squibb Company, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Viatris Inc., Bausch Health Companies Inc., Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Horizon Therapeutics plc, Seagen Inc. (formerly Seattle Genetics, Inc.)

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MYCOSIS FUNGOIDES TREATMENT MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Type
• 4.2. Topical Steroids (Corticosteroid Creams or Ointments (Hydrocortisone, Clobetasol), Topical Steroid Lotions) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Mechlorethamine (Topical Mechlorethamine (Nitrogen Mustard Cream), Injectable Mechlorethamine) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MYCOSIS FUNGOIDES TREATMENT MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Treatment Type
• 5.2. Photodynamic Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Radiation Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Targeted Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Chemotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MYCOSIS FUNGOIDES TREATMENT MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Private Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL MYCOSIS FUNGOIDES TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Type
  • 7.2.2 By Treatment Type
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Type
  • 7.3.2 By Treatment Type
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Type
  • 7.4.2 By Treatment Type
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Type
  • 7.5.2 By Treatment Type
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Type
  • 7.6.2 By Treatment Type
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL MYCOSIS FUNGOIDES TREATMENT INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Pfizer Inc
  • 9.2.2 Merck & Co.Inc
  • 9.2.3 Bristol Myers Squibb Company
  • 9.2.4 Abbott Laboratories
  • 9.2.5 Novartis AG
  • 9.2.6 GlaxoSmithKline Plc
  • 9.2.7 Takeda Pharmaceutical Company Limited
  • 9.2.8 Astellas Pharma Inc
  • 9.2.9 Daiichi Sankyo Company, Limited
  • 9.2.10 Viatris Inc
  • 9.2.11 Bausch Health Companies Inc
  • 9.2.12 Eisai Co.Ltd
  • 9.2.13 Kyowa Kirin Co.Ltd
  • 9.2.14 Horizon Therapeutics Plc
  • 9.2.15 Seagen Inc. (formerly Seattle Genetics, Inc.)